Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

被引:16
|
作者
Zhou, Hong [1 ,2 ,3 ]
Ma, Yipeng [2 ,3 ]
Liu, Fenglan [2 ,3 ]
Li, Bin [2 ,3 ]
Qiao, Dongjuan [2 ,3 ]
Ren, Peigen [1 ]
Wang, Mingjun [2 ,3 ]
机构
[1] Chinese Acad Sci, Ctr Energy Metab & Reprod, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
[2] Shenzhen Innovat Immunotechnol Co Ltd, Dept Res & Dev, Shenzhen, Peoples R China
[3] Shenzhen Inst Innovat & Translat Med, Dept Res & Dev, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
CTA; NY-ESO-1; cancer vaccine; immunotherapy; solid cancer; T-CELL RESPONSES; NY-ESO-1-SPECIFIC IMMUNE-RESPONSES; TESTIS ANTIGEN NY-ESO-1; MESSENGER-RNA; OVARIAN-CANCER; POLY-ICLC; EXPRESSING NY-ESO-1; MELANOMA PATIENTS; DENDRITIC CELLS; VACCINATION;
D O I
10.3389/fimmu.2023.1255799
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] The expression of NY-ESO-1, cancer specific antigen, in patients with hepatocellular carcinoma.
    Nakamura, S
    Nouso, K
    Taniyama, M
    Kobayasi, Y
    Nakatsukasa, H
    Uemura, M
    Sato, S
    Yumoto, E
    Yokoyama, J
    Tsuboi, S
    Higashi, T
    Tsuji, T
    HEPATOLOGY, 2001, 34 (04) : 180A - 180A
  • [42] Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions
    Murphy, R
    Green, S
    Ritter, G
    Cohen, L
    Ryan, D
    Woods, W
    Rubira, M
    Cebon, J
    Davis, ID
    Sjolander, A
    Kypridis, A
    Kalnins, H
    McNamara, M
    Moloney, MB
    Ackland, J
    Cartwright, G
    Rood, J
    Dumsday, G
    Healey, K
    Maher, D
    Maraskovsky, E
    Chen, YT
    Hoffman, EW
    Old, LJ
    Scott, AM
    PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, 2005, 35 (02): : 119 - 134
  • [43] Seminal expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer
    Satie, Anne-Pascale
    Auger, Jacques
    Chevrier, Cecile
    Le Bon, Cynthia
    Jouannet, Pierre
    Samson, Michel
    Jegou, Bernard
    INTERNATIONAL JOURNAL OF ANDROLOGY, 2009, 32 (06): : 713 - 719
  • [44] Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer
    Saito, Takuro
    Kurkawa, Yukinori
    Fujitani, Kazumasa
    Kawabata, Ryohei
    Takeno, Atsushi
    Mikami, Jota
    Endo, Shunji
    Matsuyama, Jin
    Akamaru, Yusuke
    Hirota, Masashi
    Kishi, Kentaro
    Tanaka, Koji
    Takahashi, Tsuyoshi
    Wada, Hisashi
    Eguchi, Hidetoshi
    Doki, Yuichiro
    CANCER SCIENCE, 2025, 116 : 488 - 488
  • [45] Screening for the cancer immunotherapy target NY-ESO-1 in soft-tissue sarcoma
    Sellner, L.
    Chudasama, P.
    Renner, M.
    Gong, W.
    Heilig, C. E.
    Egerer, G.
    Shiku, H.
    Mechtersheimer, G.
    Mueller-Tidow, C.
    Froehling, S.
    Gdynia, G.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 111 - 111
  • [46] Prognostic value of MAGE-3 and NY-ESO-1 expression in pharyngeal cancer
    Sarcevic, B.
    Pastorcic-Grgic, M.
    Dosen, D.
    Knezevic, F.
    VIRCHOWS ARCHIV, 2009, 455 : 339 - 339
  • [47] Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)
    Julve, Max
    Kennedy, Oliver
    Frampton, Adam Enver
    Bagwan, Izhar
    Lythgoe, Mark P.
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (01) : 1 - 7
  • [48] PROMOTER DEMETHYLATION OF NY-ESO-1 PRIMES GLIOBLASTOMA FOR IMMUNOTHERAPEUTIC TARGETING.
    Lai, Thomas
    Treger, Janet
    Rao, Jingyou
    Sun, Lu
    Li, Tie
    Lai, Albert
    Prins, Robert
    Everson, Richard G.
    NEURO-ONCOLOGY, 2022, 24 : 133 - 134
  • [49] A Novel Murine T-Cell Receptor Targeting NY-ESO-1
    Rosati, Shannon F.
    Parkhurst, Maria R.
    Hong, Young
    Zheng, Zhili
    Feldman, Steven A.
    Rao, Mahadev
    Abate-Daga, Daniel
    Beard, Rachel E.
    Xu, Hui
    Black, Mary A.
    Robbins, Paul F.
    Schrump, David A.
    Rosenberg, Steven A.
    Morgan, Richard A.
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (03) : 135 - 146
  • [50] Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
    Everson, Richard G.
    Antonios, Joseph P.
    Lisiero, Dominique N.
    Soto, Horacio
    Scharnweber, Rudi
    Garrett, Matthew C.
    Yong, William H.
    Li, Ning
    Li, Gang
    Kruse, Carol A.
    Liau, Linda M.
    Prins, Robert M.
    NEURO-ONCOLOGY, 2016, 18 (03) : 368 - 378